Figure 1: rAAV administration in Substantia Nigra. | Scientific Reports

Figure 1: rAAV administration in Substantia Nigra.

From: Recombinant Adeno-Associated Virus-mediated rescue of function in a mouse model of Dopamine Transporter Deficiency Syndrome

Figure 1

(A) Surgery. Adult DAT-KO mice underwent bilateral stereotaxic injection of AAV particles in the SN (coordinates: −3.2 mm AP, ±1.2 ML, −4.3 DV), where DA neurons originate and project to the striatum. (B) Dual combinatoral AAV strategy. TH-iCRE-AAV is used to confer the selective expression of improved CRE recombinase protein (iCRE – orange box) in DA neurons under control exerted by the 2.5 kilobase Rat Tyrosine Hydroxylase promoter (Rat TH – blue arrow). This construct was delivered in a 1:1 ratio with AAV constructs bearing an inverted sequence – indicated by a flipped (leftward) arrow – of the gene of interest under control of CMV promoter (CMV – white arrow). For the DAT-KO control group, the AAV construct bore the tdTOMATO gene sequence (CMV-DIO-tdTOMATO-AAV, magenta arrow), while for the DAT-KO treated group, the AAV bore the inverted sequence of the mouse Dopamine Transporter (mDAT) gene, depicted with a teal arrow (CMV-DIO-mDAT-AAV). (C) Experimental paradigm. Mice underwent surgery at postnatal day 70 (day 0) and were tested every 12 days.

Back to article page